As with salivary gland tumors, thyroid cancer constitutes a spectrum of histologic subtypes and clinical
Table 22-10. COMBINATION CHEMOTHERAPY IN SALIVARY GLAND CANCER
No. of Patients
Overall Response Rates (%)
CDDP/5-FU CDDP/DOXO/5-FU CDDP/EPI/5-FU or CTX CTX/DOXO CTX/DOXO/CDDP
Adenoid cystic Mucoepidermoid Mucoepidermoid 'Variable 'Variable 'Variable 'Variable
25 33 33 35 45 45 50
* Variable: includes adenoid cystic carcinoma and mucoepidermoid carcinoma as the most common histologies.
BLM = bleomycin; CDDP = cisplatin; CT = chemotherapy; CTX = cyclophosphamide; DOXO = doxorubicin; 5-FU = 5-fluorouracil; EPI :
methotrexate; VCR = vincristine.
behaviors that should be considered when making decisions regarding the role of systemic therapy. Chemotherapy is most commonly considered after surgery and/or radiation therapy (external beam, and if applicable, radioactive iodine [RAI]) have failed, as induction/adjuvant chemotherapy is of unproven benefit. Chemotherapy by itself is not a curative modality. The available data to aid clinical decision-making is limited in both quantity and quality. Investigational studies from the start are appropriate to consider.
For differentiated histologies (eg, papillary or follicular), radioactive iodine (RAI) is the initial systemic therapy of choice. Before considering chemotherapy, evaluating the adequacy and quality of prior therapy with RAI should be the first step. For example, recent intravenous iodinated contrast, con sumption of an iodine-rich diet, inadequate levels of thyroid stimulating hormone (TSH), or persistence of a significant amount of native thyroid cancer may all affect the efficacy of RAI treatment for the tumor. For RAI-refractory disease, initial observation is appropriate for selected patients, as the tumor may grow slowly. If chemotherapy is indicated, doxorubicin is the most studied and widely used drug, with response rates in the 30 to 40 percent range.148,149 Cisplatin, carboplatin, methotrexate, and etoposide also have activity.150 Combination chemotherapy may improve response rate but has unproven benefit in terms of palliation and survival. Chemotherapy and radiation have been combined for the treatment of compelling local disease with good local effect in most patients.151152 The possible use of agents intended to
differentiate the tumor (eg, retinoids) and help it regain RAI avidity is an area of active interest.153
Anaplastic thyroid cancer is an aggressive subtype with a poor prognosis even with the best available therapy. Generally these tumors are unresectable at presentation and are not RAI avid. Combined modality chemotherapy/radiation programs 151,152 are commonly employed initially in the management of these cancers with reported improvement compared to historical results with radiation alone. There are, however, no randomized data, and survival statistics remain disappointing. When chemotherapy is employed alone, one randomized trial reported a higher complete response when doxorubicin and cisplatin were combined compared to doxorubicin alone.154 Of note, a large cell lymphoma of the thyroid can present in a manner similar to anaplastic thyroid cancer, but the former will have a better prognosis and chemotherapy for the disease is much more effective. Accordingly, the initial pathology review is extremely important.
Medullary carcinoma is another cancer that can behave in an indolent manner, where initial observation in order to get a sense of disease trajectory is often a good option for the patient. Streptozocin, cyclophosphamide, dacarbazine, and 5-fluorouracil appear to have some activity, alone or in combination, but only a minority of patients will have a major response.155,156 Many of these patients will suffer from troublesome diarrhea for which debulk-ing of gross tumor or a trial of octreotide or inter-feron-a may be helpful.157,158 Occasionally these patients will present to the medical oncologist without appropriate screening studies having been done to rule out a familial syndrome. If so, an appropriate screening evaluation should be initiated.
1. Weissler MC, Melin S, Sailer SL, et al. Simultaneous chemoradiation in the treatment of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 1992; 118:806-10.
2. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without chemotherapy for locally advanced head and neck cancer. N Engl J Med 1997;338:1798-804.
3. Wendt TG, Grabenbauer GG, Rödel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized study. J Clin Oncol 1998;16:1318-24.
4. Merlano M, Benasso M, Corvo R, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996;88:583-9.
5. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiother-
apy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol 1998;16:1310-7.
6. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-86.
7. The Department of Veterans Affairs Laryngeal Cancer Study
Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-90.
8. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preser vation in pyriform sinus cancer: preliminary results from a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-9.
9. Hong WK, Endicott J, Itri LM, et al. 13-ci.s-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315:1501-5.
10. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15-20.
11. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323: 795-801.
12. Bolla M, Lefur R, Ton Van J, et al. Prevention of second pri mary tumors with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicen-tric double-blind randomised study. Eur J Cancer 1994; 30A:767-72.
13. Sauer R, Wannenmacher M, Wasserman T, et al. Randomized phase III trial of radiation with or without amifostine in patients with head and neck cancer. Proc Am Soc Clin Oncol 1999;18:392.
14. Rieke JW, Hafermann MD, Johnson JT, et al. Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys 1995;31:661-9.
15. Piccirillo JF. Inclusion comorbidity in a staging system for head and neck cancer. Oncology 1995;9:831-6.
16. Shaha AR, Hoover EL, Mitrani M, et al. Synchronicity, mul-
ticentricity and metachronicity of the head and neck cancer. Head Neck 1988;10:225-8.
17. Head and Neck Contracts Program. Adjuvant chemotherapy for advanced head and neck squamous carcinoma: final report of the Head and Neck Contracts Program. Cancer 1987;60:301-11.
18. Beziak A, Grilli R, Browman G. Non-resectability in radio therapy trials in squamous cell carcinoma of the head and neck—implications for generalizability of trials results. Proc Am Soc Clin Oncol 1995;14:296.
19. Vokes EE, Weichselbaum RR. Concomitant chemoradiother-
apy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 1990;8:911-34.
20. Schantz SP, Harrison LB, Forastiere AA. Tumors of nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: De Vita V Jr, Hellman S, Rosenberg SA, editors. Principles of Practice and Oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1997. p. 741801.
21. Smith RE, Thornton DE, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratories studies. Semin Oncol 1995;22 (3 Suppl 6):41-46.
22. Gebbia V, Testa G, Cannata G, et al. Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer 1996;32A:901-2.
23. Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel with advanced squamous cell carcinoma of the head and neck. Cancer 1998;82: 2270-4.
24. Vermorken JB, Catimel G, de Mulder P, et al. Randomized phase II trial of weekly methotrexate (MTX) versus two schedules or triweekly paclitaxel (Taxol®) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 1999;18:395.
25. Catimel G, Verwij J, Hanauske A. Docetaxel (taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:533-7.
26. Dreyfuss AI, Clark J, Norris C, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14:1672-8.
27. Colevas D, Posner MR. Docetaxel in head and neck cancer.
Am J Clin Oncol 1998;21:482-6.
28. Huber MH, Lippman SM, Benner SE, et al. A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. Am J Clin Oncol 1996;19:379-83.
29. Buesa JM, Fernandez R, Esteban E, et al. Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. Ann Oncol 1991;2:151-2.
30. Martin M, Diaz-Rubio E, Gonzales-Larriba JL, et al. Ifos-
famide in advanced epidermoid head and neck cancer. Cancer Chemother Pharmacol 1993;31:340-2.
31. Cervellino JC, Araujo CE, Pirisi C, et al. Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. Oncology 1991;48:89-92.
32. Catimel G, Vermorken JB, Clavel M, et al. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:543-7.
33. Lippman SM, Bronner SE, Hong WK. Cancer chemopreven-
tion. J Clin Oncol 1994;12:851-73.
34. Kish J, Drelichman A, Jacobs J, et al. Clinical trial of cis platin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 1982;66:471-4.
35. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III and IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della
Testa e del Collo. J Natl Cancer Inst 1994;86:265-72.
36. Colevas AD, Busse PM, Norris CM, et al. Induction chemo therapy with docetaxel, cisplatin, 5-fluorouracil, leucov-orin (TPFL5) for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998;16:1331-9.
37. Dunphy F, Boyd J, Dunleavy T. Paclitaxel and carboplatin in head and neck cancer. Semin Oncol 1997;24(6 Suppl 19): 25-27.
38. Hitt R, Hornedo J, Colomer R, et al. Study of escalating doses of paclitaxel and cisplatin in patients with inoperable head and neck cancer. Semin Oncol 1997;24(1 Suppl 2):58-64.
39. Wang H-M, Wang C-H, Chen J-S, Lin Y-C. Cisplatin (C), tegafur (T), leucovorin (L): an effective, less toxic, and outpatient neoadjuvant chemotherapy (CT) for squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 1999;18:400.
40. Gebbia V Mantovani G, Farris A, et al. Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II study. Cancer 1997; 79:1394-400.
41. Rivera F, Lopez-Brea M, Pascual C, et al. Interim analysis of a phase III study of cisplatin and 5-FU continuous infusion (PF) vs. cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy (IC) in locally advanced squa-mous cell head and neck cancer (SCHNC). Proc Am Soc Clin Oncol 1999;18:399.
42. Pai VR, Mazumdar AT, Parikh DM, et al. Gemcitabine with ifosfamide, cisplatin combination chemotherapy in advanced head and neck cancer. Proc Am Soc Clin Oncol 1999;18:408.
43. Hartsell WF, Thomas CR, Murthy AK, et al. Pilot study for the evaluation of simultaneous cisplatin/5-fluorouracil infusion and limited radiation therapy in regionally recurrent head and neck cancer. Am J Clin Oncol 1998;17:338-43.
44. De Crevoisier R, Bouhris J, Domenge C, et al. Full-dose reir radiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998;16:3556-62.
45. Mossman KL. Frequent short-term oral complications of head and neck radiotherapy. Ear Nose Throat J 1994; 73:316-20.
46. El-Sayed S, Nelson N. Adjuvant and adjunctive chemother apy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective randomized trials. J Clin Oncol 1996;14:838-47.
47. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncol ogy Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: preliminary results ot RTOG 9003. Int J Radiat Oncol Biol Phys 1999; 45:145.
48. Adelstein DJ. Induction chemotherapy in head and neck can cer. Hematol Oncol Clin North Am 1999;13:689-98.
49. Schuller DE, Metch B, Mattox D, et al. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 1988;98:1205-11.
Laramore GE, Scott CB, Al-Sarraf M, et al, Adjuvant 66. chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup study 0034.Int J Radiat Oncol Biol Phys 1992;23:705-13.
Richard JM, Kramar A, Molinari R, et al. Randomised 67. EORTC head and neck cooperative group trial of preop-erative intra-arterial chemotherapy in oral cavity and oropharynx carcinoma. Eur J Cancer 1991;27:821-7. 68.
Depondt J, Gehanno P, Martin M, et al. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer. Oncology 1993;50(Suppl 2):23-7.
Dalley D, Beller E, Aroney R, et al. The value of chemother- 69. apy (CT) prior to definitive local therapy (DLT) in patients with locally advanced squamous cell carcinoma (SCC) of the head and neck (HN). Proc Am Soc Clin Oncol 1995;14:297. 70.
Domenge C, Marandas P, Vignoud J, et al. Post-surgical adjuvant chemotherapy in extra-capsular spread invaded node (N + R + ) of epidermoid carcinoma of the head and neck. A randomized multicentric trial. Second International Conference in Head and Neck, Boston, 1988. Am Soc 71 Head Neck Surg 1988;74. .
Horiuchi M, Inuyama Y, Miyake H, and the Head and Neck UFT Study Group. Efficacy of surgical adjuvant with tegafur and uracil (UFT) in resectable head and neck cancer: a prospective randomized study. Proc Am Soc Clin Oncol 1994;13:284. 72
Di Blasio B, Barbieri W, Bozzetti A, et al. A prospective randomized trial in resectable head and neck carcinoma: loco-regional treatment with and without neoadjuvant chemotherapy. Proc Am Soc Clin Oncol 1994;13:279. 73
Jacobs C, Makuch R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the head and neck contracts program. J Clin Oncol 1990;8:838-47.
Ervin TJ, Clark JR, Weichselbaum RR, et al. An analysis of induction and adjuvant chemotherapy in the multidiscipli-nary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 1987;5:10-20.
Stell PM. Adjuvant chemotherapy in head and neck cancer. Semin Radiat Oncol 1992;2:195-205.
Browman GP, Cronin L. Standard chemotherapy in squa-
mous cell head and neck cancer: what we have learned 75. from randomized trials. Semin Oncol 1994;21:311-9.
Bourhis J, Pignon JP, Designé L, et al. Meta-analysis of chemotherapy in head and neck (MACH-NC): (1) Loco-regional treatment vs same treatment + chemotherapy (CT). Proc Am Soc Clin Oncol 1998;17:386. 76.
Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995;71:83-91.
Shanta V, Krishnamurthi S. Combined bleomycin and radio- 77. therapy in oral cancer. Clin Radiol 1980;31:617-20.
Sanchíz F, Milla A, Torner J, et al. Single-fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19:1347-50. 78.
Browman GP, Cripps C, Hodson DI, et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 1994;12:2648-53.
Gupta NK, Pointon RCS, Wilkinson PM. A randomized clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin Radiol 1987;38:575-81.
Weissberg JB, Son YH, Papac RJ, et al. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1989;17:3-9.
Lo TC, Wiley AL Jr, Ansfield FJ, et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am J Roentgenol 1976;126:229-35.
Arcangeli G, Nervi C, Righini R, et al. Combined radiation and drugs: the effect of intra-arterial chemotherapy followed by radiotherapy in head and neck cancer. Radiother Oncol 1983;1:101-7.
Fu KK, Phillips TL, Silverberg IJ, et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987;5:1410-8.
Eschwege F, Sancho-Garnier H, Gerard JP, et al. Ten-year results of randomized trial comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epider-moid carcinomas of the oropharynx: experience of the European Organization for Research and Treatment of Cancer. NCI Monogr 1988;6:275-8.
Vermund H, Kaalhus O, Winther F, et al. Bleomycin and radiation therapy in squamous cell carcinoma of the upper aero-digestive tract: a phase III clinical trial. Int J Radiat Oncol Biol Phys 1985;11:1877-86.
Gabriele P, Tessa M, Ragona R, et al. An interim analysis of phase III study on radiotherapy (RT) versus RT plus car-boplatin (CBDCA) in inoperable stage III-IV head and neck (H&N) carcinoma. Proceedings of the 4th International Conference on Head and Neck Cancer 1996; Toronto, Canada.
Haselow RE, Warshaw MG, Oken MM, et al. Radiation alone versus radiation with weekly low-dose cisplatinum in unresectable cancer of the head and neck. In: Fee WE Jr, Goepfert H, Johns ME, et al., editors. Head and Neck, vol. II. Philadelphia: JB Lippincott; 1990. p. 279-81.
Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36:999-1004.
Dobrowsky W, Naude J, Widder J, et al. Continuous hyper-fractionated radiotherapy with/without mitomycin C in head and neck cancer. Int J Radiat Oncol Biol Phys 1998;42:803-6.
Aldelstein DJ, Saxton JP, Lavertu P, et al. A phase III trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 1997;19:567-75.
Adelstein DJ, Lavertu P, Saxton JP, et al. Long-term results of a phase III randomized trial comparing concurrent chemoradiotherapy and radiation therapy (RT) alone in squamous cell head and neck cancer (SCHNC). Proc Am Soc Clin Oncol 1999;18:394.
79. Keane TJ, Cummings BJ, O'Sullivan B, et al. A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5- fluo-rouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys 1993;25:613-8.
80. Lavertu P, Bonafede JP, Aldestein DJ, et al. Comparison of surgical complications after organ-preservation therapy in patients with stage III or IV squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg 1998;124: 401-6.
81. A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck. An interim report from the SECOG participants. South-East Co-operative Oncology Group. Eur J Surg Oncol 1986;12:289-95.
82. Adelstein DJ, Sharan VM, Earle AS, et al. Simultaneous ver sus sequential combined technique therapy for squamous cell head and neck cancer. Cancer 1990;65:1685-91.
83. Merlano M, Rosso R, Sertoli MR, et al. Randomized com parison of two chemotherapy, radiotherapy schemes for stage III and IV unresectable squamous cell carcinoma of the head and neck. Laryngoscope 1990;100:531-5.
84. Taylor IVSG, Murthy AK, Vannetzel JM, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994;12:385-95.
85. Kies MS, Haraf DJ, Athanasiadis I, et al. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol 1998;16:2715-21.
86. Sherman E, Pfister DG, Harrison L, et al. A comparison of concomitant cisplatin with accelerated radiation therapy versus conventional RT as part of larynx preservation strategy: results of multivariate analysis. Proc Am Soc Clin Oncol 1998.
87. Pfister DG, Harrison LB, Strong EW, Bosl GJ. Current status of larynx preservation with multimodality therapy. Oncol 1994;6:33-43.
88. Pfister DG, Strong E, Harrison L, et al. Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer. J Clin Oncol 1991;9:850-9.
89. Karp DD, Vaughan CW, Carter R, et al. Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer. A long-term follow-up report. Am J Clin Oncol 1991;14:273-9.
90. McNeil BJ, Weichselbaum R, Pauker SG. Speech and sur vival: trade-offs between quality of life in laryngeal cancer. N Engl J Med 1981;305:982-7.
91. Harwood AR, Rawlinson E. The quality of life of patients fol lowing treatment for advanced laryngeal cancer. Int J Radiat Oncol Biol Phys 1983;9:335-8.
92. De Santo LW. T3 glottic cancer: options and consequences of the options. Laryngoscope 1984;94:1311-5.
93. Kazem I, van den Broek P, Huygen PL. Planned preoperative radiation therapy vs. definitive radiotherapy for advanced laryngeal carcinoma. Laryngoscope 1984;94:1355-8.
94. Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998;34:224-8.
95. Wolf GT, Hong WK, Fisher SG. Neoadjuvant chemotherapy for organ preservation: current status. Proceedings of the 4th International Conference in Head and Neck Cancer 1996;4:89-97.
96. Terrel JE, Fisher SG, Wolf GT. Long-term quality of life after the treatment of laryngeal cancer. Arch Otolaryngol Head Neck Surg 1998;124:964-71.
97. Lefebvre JL, Wolf G, Luboinski B, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): (2) Larynx preservation using neoadjuvant chemotherapy (CT) in laryngeal and hypopharyngeal carcinoma. Proc Am Soc Clin Oncol 1998;17:382.
98. Hensley ML, Schuchter LM, Lindley C, et al. American
Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17:3333-55.
99. Buntzel J, Kuttner K, Frohlich, Glatzel M. Selective cytopro-
tection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 1998;9:505-9.
100. Bohuslavizki KH, Klutmann S, Brenner W, et al. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. J Clin Oncol 1998;16:3542-9.
101. Jacobs CD, van der Pas M. A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. Oncology (Huntingt) 1996;10 (3 Suppl):16-20.
102. Ning S, Shuii C, Khan WB, et al. Effects of keranocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma in vitro and in vivo. Int J Radiat Oncol Biol Phys 1997;40:177-87.
103. Plevova P. Prevention and treatment of chemotherapy—and radiotherapy—induced oral mucositis: a review. Oral Oncol 1999;35:453-70.
104. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squa-mous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-51.
105. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III ran domized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10:257-63.
106. Clavel M, Vermoken JB, Cognetti F, et al. A randomized com parison of cisplatin, methotrexate, bleomycin and vin-cristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:521-6.
107. Clayman GL, el-Naggar AK, Lipmann SM, et al. Aden-
ovirus-mediated p53 transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:2221-32.
108. Brown D, Wang R, Russel P. Antiepidermal growth factor receptor antibodies augment cytotoxicity of chemothera-peutic agents on squamous cell carcinoma cell lines. Otolaryngol Head Neck Surg 2000;122:75-83.
109. Micheau C, Boussen H, Klijanienko J, et al. Bone marrow biopsies in patients with undifferentiated carcinoma of nasopharyngeal type. Cancer 1987;60:2459-64.
110. International Nasopharynx Cancer Study Group: VUMCA I
trial. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (> N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 1996;35:463-9.
111. Rossi A, Molinari R, Boracchi M, et al. Adjuvant chemother apy with vincristine, cyclophosphamide, and adriamycin after radiotherapy in loco-regional nasopharyngeal cancer: result of a 4-year multicenter randomized study. J Clin Oncol 1988;6:1401-10.
112. Chan ATC, Teo PML, Leung WT, et al. A prospective ran domized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Biol Phys 1995;33:569-77.
113. Fandi A, Altun M, Azli M, et al. Nasopharyngeal cancer: epi demiology, staging, and treatment. Semin Oncol 1994; 21:382-97.
114. Mahjoubi R, Azli N, Bachouchi M, et al. Metastatic (MTS)
undifferentiated carcinoma of nasopharyngeal type (UCNT) treated with bleomycin (B), epirubucin (E) and cisplatin (P) (BEC). Final report. Proc Am Soc Clin Oncol 1992;11:772.
115. Shiu WCT, Tsao SY. Efficacy of 4'-epidoxorubicin (phar-
morubicin) in advanced nasopharyngeal carcinoma. Clinical Trials Journal 1989;26:419.
116. Dugan M, Choy D, Ngai A, et al. Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanic Clinical Oncology Association Group study. J Clin Oncol 1993; 11:70-6.
117. Au E, Ang PT, Chua EJ. Paclitaxel in metastatic nasopharyn geal cancer. Proc Am Soc Clin Oncol 1996;15:919.
118. Taamma A, Fandi A, Azli N, et al. 5 fluorouracil (FU), bleomycin (BLM), epirubicin (E), cisplatin (P) in locally advanced (LA), recurrent and/or metastatic (REC/MTS) undifferentiated carcinoma nasopharyngeal type. (UCNT) preliminary activity/toxicity report. Proc Am Soc Clin Oncol 1996;15:909.
119. Slaughter DP, Southwick HW, Smejkal W. "Field canceriza-
tion" in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963-8.
120. Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expres sion in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54:321-6.
121. Renan MJ. How many mutations are required for tumorigen-
esis? Implications from human cancer data. Mol Carcinog 1993;7:139-46.
122. Vokes EE, Weichselbaum RR, Lipman S, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
123. Lotan R. Retinoids in cancer chemoprevention. FASEB J
124. Mangelsdorf DJ, Umesono K, Evans RM. The retinoid recep tors. In:Sporn MB, Roberts AB, Goodman DS, editors. The retinoids. New York: Raven Press; 1994. p. 319-49.
125. Nagy L, Thomazy VA, Shipley GL, et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 1995;15:3540-51.
126. Stich HF, Hornby AP, Mathew B, et al. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988;40:93-101.
127. Papadimitrakopoulou VA, Hong WK, Lee JS, et al. Low-dose isotretinoin versus ß-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst 1997;89:257-8.
128. Chiesa F, Tradati N, Marazza M, et al. Fenretidine (4-HPR)
in chemoprevention of oral leukoplakia. J Cell Biochem Suppl 1993;17:255-61.
129. Benner SE, Pajak TF, Lippman SM, et al. Prevention of sec ond primary tumors with isotretinoin in squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994;86:140-1.
130. Van Zandwijk N, Pastorino U, De Vries N, et al. Randomized trial of chemoprevention with vitamin A and N-acetylcys-teine in patients with cancer of the upper and lower airways: the Euroscan study. Proc Am Soc Clin Oncol 1999; 18:464.
131. Papadimitrakopoulou VA, Shin DM, Hong WK. Chemopre-
vention of head and neck cancer. In: Harrison LB, Sessions RB, Hong WK, editors. Head and neck cancer: a multidisciplinary approach. Philadelphia: LippincottRaven Publishers; 1999. p. 49-75.
132. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial. J Natl Cancer Inst 1996;88:1550-9.
133. Albanes D, Heinonen OP, Taylor PR, et al. a-Tocopherol and
ß-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996;88:1560-70.
134. Spiro RH, Koss LG, Hajdu SI, et al. Tumors of minor salivary gland origin: a clinicopathologic study of 492 cases. Cancer 1973;31:117-30.
135. Spiro R, Spiro J. Cancer of the salivary glands. In: Meyers E,
Suen J, editors. Cancer of the head and neck. 2nd ed. New York: Churchill Livingstone; 1984. p. 644-99.
136. Suen J, Johns M. Chemotherapy for salivary gland cancer.
137. Tannock IF, Sutherland DJ. Chemotherapy for adenocystic carcinoma. Cancer 1980;46:452-4.
138. Schramm V Jr, Srodes C, Myers C. Cisplatin therapy for ade noid cystic carcinoma. Arch Otolaryngol 1981;107:739-41.
139. Licitra L, Marchini S, Spinazze S, et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 1991;68:1874-7.
140. Jones AS, Phillips DE, Cook JA, Helliwell TR. A randomized phase II trial of epirubicin and 5-fluorouracil versus cis-platinum in the palliation of advanced and recurrent malignant tumour of the salivary glands. Br J Cancer 1993;37:112-4.
141. Airoldi M, Brando V Giordano C, et al. Chemotherapy for recurrent salivary gland malignancies: experience of the ENT Department of Turin University. ORL J Otorhino-laryngol Relat Spec 1994;56:105-11.
142. Rentscheler R, Burgess MA, Byers R. Chemotherapy for malignant salivary gland neoplasms: a 25-year review of M.D. Anderson Hospital experience. Cancer 1977;40: 619-24.
143. Triozzi PL, Brantley A, Fisher S, et al. 5-fluourouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Cancer 1987;59:887-90.
144. Posner MR, Ervin TJ, Weichselbaum RR, Fabian RL.
Chemotherapy of advanced salivary gland neoplasms. Cancer 1982;50:2261-4.
145. Venook AP, Tseng A, Meyers FJ, Silverberg I. Cisplatin, dox orubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 1987;5:951-5.
146. Dimery IW, Legha SS, Shirinian M, Hong WK. Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 1990;8:1056-62.
147. National Comprehensive Cancer Network guidelines. Oncol ogy. In press. 2000.
148. Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 1974;290:193-7.
149. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999;16:34-41.
150. Hoskin PJ, Harmer C. Chemotherapy for thyroid cancer.
Radiother Oncol 1987;10:187-94.
151. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60:2372-5.
152. Tennwall J, Lundell G, Hallquist A, Wahlberg P. Combined doxorubicin, hyperfractionated radiotherapy, surgery in anaplastic thyroid carcinoma: report on two protocols. Cancer 1994;74:1348-54.
153. Börner AR, Simon D, Müller-Gärtner HW. Isotretinoin in metastatic thyroid cancer. Ann Int Med 1997;127:246.
154. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH. Ran domized trial of doxorubicin versus doxorubicin plus cisplatin with advanced thyroid carcinoma. Cancer 1985; 56:2155-60.
155. Schlumberger M, Abdelmoumene N, Deslisle NJ, the Groupe d'Études des Tumeurs a Calcitonine (GETC). Treatment for advanced medullary thyroid cancer with an alternating combination of 5-FU-streptozocin and 5 FU-dacarbazine. Brit J Cancer 1995;71:363-5.
156. Wu LT, Averbuch SD, Ball DW, et al. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 1994;73:432-6.
157. Vitale G, Tagliaferri P, Caraglia M, et al. Slow release lan-
reotide in combination with interferon-alpha2b in the treatment of symptomatic advanced thyroid carcinoma. J Clin Endocrinol Metab 2000;85:983-8.
158. Lupoli G, Cascone E, Arlotta F, et al. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Cancer 1995;78:1114-8.
Was this article helpful?